State of the Globe: A Glimmer of Hope - Biomarkers for Diagnosing COVID-19 Pulmonary Fibrosis.
作者信息
Ghatak Tanmoy, Thakur Suman
机构信息
Department of Emergency Medicine, SGPGIMS, Lucknow, Uttar Pradesh, India.
Department of Microbiology, IGMC, Shimla, Himachal Pradesh, India.
出版信息
J Glob Infect Dis. 2024 Jun 26;16(2):43-44. doi: 10.4103/jgid.jgid_119_24. eCollection 2024 Apr-Jun.
Abstract
摘要
相似文献
1
State of the Globe: A Glimmer of Hope - Biomarkers for Diagnosing COVID-19 Pulmonary Fibrosis.全球状况：一线希望——用于诊断新冠肺纤维化的生物标志物
J Glob Infect Dis. 2024 Jun 26;16(2):43-44. doi: 10.4103/jgid.jgid_119_24. eCollection 2024 Apr-Jun.
2
Serum prealbumin as prognostic indicator in idiopathic pulmonary fibrosis. A glimmer of hope.血清前白蛋白作为特发性肺纤维化的预后指标。一线希望。
Clin Respir J. 2019 Oct;13(10):659-660. doi: 10.1111/crj.13072. Epub 2019 Aug 23.
3
Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis.尼达尼布与肺纤维化疾病症状：肺纤维化患者的一线希望之光。
Eur Respir J. 2024 Feb 1;63(2). doi: 10.1183/13993003.00067-2024. Print 2024 Feb.
4
NHS homes fund could offer a glimmer of hope.
Nurs Stand. 2017 Jul 26;31(48):30. doi: 10.7748/ns.31.48.30.s26.
5
Preventing Obesity in Children: A Glimmer of Hope.预防儿童肥胖：一线希望。
JAMA. 2018 Aug 7;320(5):443-444. doi: 10.1001/jama.2018.9442.
6
Myocardial work index: a glimmer of hope in COVID-19.心肌工作指数：新冠疫情中的一线希望。
Eur Heart J Cardiovasc Imaging. 2021 Jan 22;22(2):228. doi: 10.1093/ehjci/jeaa181.
7
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.抗纤维化药物治疗特发性肺纤维化和 COVID-19 引起的肺纤维化：治疗方法和潜在的诊断生物标志物。
Int J Mol Sci. 2024 Jan 26;25(3):1562. doi: 10.3390/ijms25031562.
8
A Glimmer of Hope.
J Am Geriatr Soc. 2018 Dec;66(12):2241-2242. doi: 10.1111/jgs.15649. Epub 2018 Nov 19.
9
Post-COVID-19 pulmonary fibrosis: An ongoing concern.新冠病毒感染后肺纤维化：持续受到关注。
Ann Thorac Med. 2023 Oct-Dec;18(4):173-181. doi: 10.4103/atm.atm_7_23. Epub 2023 Oct 17.
10
A Glimmer of Hope for an Orphan Disease.
N Engl J Med. 2023 Jul 6;389(1):81-82. doi: 10.1056/NEJMe2304147. Epub 2023 Jun 22.
本文引用的文献
1
Post-COVID-19 pulmonary fibrosis: An ongoing concern.新冠病毒感染后肺纤维化：持续受到关注。
Ann Thorac Med. 2023 Oct-Dec;18(4):173-181. doi: 10.4103/atm.atm_7_23. Epub 2023 Oct 17.
2
Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.新冠后肺纤维化：事实、挑战与未来：一篇叙述性综述
Pulm Ther. 2023 Sep;9(3):295-307. doi: 10.1007/s41030-023-00226-y. Epub 2023 May 20.
3
Chemokine-Based Therapeutics for the Treatment of Inflammatory and Fibrotic Convergent Pathways in COVID-19.基于趋化因子的疗法用于治疗COVID-19中的炎症和纤维化趋同通路
Curr Pathobiol Rep. 2021;9(4):93-105. doi: 10.1007/s40139-021-00226-0. Epub 2021 Dec 8.
4
Serum KL-6 concentrations as a novel biomarker of severe COVID-19.血清 KL-6 浓度作为严重 COVID-19 的新型生物标志物。
J Med Virol. 2020 Oct;92(10):2216-2220. doi: 10.1002/jmv.26087. Epub 2020 Jun 9.
5
A potential treatment of COVID-19 with TGF-β blockade.一种通过阻断转化生长因子-β来治疗新型冠状病毒肺炎的潜在方法。
Int J Biol Sci. 2020 Apr 21;16(11):1954-1955. doi: 10.7150/ijbs.46891. eCollection 2020.
6
Gross examination report of a COVID-19 death autopsy.一份新冠死亡病例尸检大体检查报告。
Fa Yi Xue Za Zhi. 2020 Feb;36(1):21-23. doi: 10.12116/j.issn.1004-5619.2020.01.005. Epub 2020 Feb 25.
7
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib.使用尼达尼布治疗的特发性肺纤维化患者的连续KL-6分析
Respir Investig. 2019 May;57(3):290-291. doi: 10.1016/j.resinv.2019.02.001. Epub 2019 Feb 21.
Zotero 插件